Immutep (ASX:IMM) has confirmed it’s dosed the first human patient with its LAG-3 based autoimmune drug candidate IMP761. LAG-3 – which stands for Lymphocyte Activation Gene 3 – is believed to be able to interfere with haywire T cells in the human body, the underlying cause of many autoimmune conditions. T Cells and lymphocyte irregularities predict many types of blood cancer. IMP761 is intended to “specifically [silence] autoimmune memory T cells that accumulate at disease sites.” However, the company pointed at rheumatoid arthritis, type 1 diabetes and multiple sclerosis in its announcement …